August 25, 2026: Blue Cloud Softech Solutions Limited has received in-principle approval from its Board to evaluate and negotiate the proposed acquisition of up to 100% of US-based CareTech AI Inc., in a transaction that could expand the company’s presence in artificial intelligence and healthcare technology.

Author: Aadarsh Patel | EQMint

The proposed acquisition would include CareTech AI and its wholly owned subsidiaries, CareCareer Tech LLC and Envision NJ LLC. The consideration is proposed to be paid through a share swap via preferential allotment of Blue Cloud Softech equity shares, subject to due diligence, valuation, regulatory approvals and definitive agreements.

CareTech AI Reported $80.2 Million Revenue in 2025

CareTech AI is a US-based AI-first healthcare technology and services company.

Through CareCareer Tech, the group operates an AI-enabled healthcare workforce platform serving acute, post-acute, behavioural health, school and correctional healthcare systems across the United States.

Its second subsidiary, Envision NJ, provides enterprise automation and orchestration solutions.

According to figures provided by CareTech AI’s management, the target group generated approximately US$80.2 million in revenue during calendar year 2025.

For the 7 months ended July 31, 2026, revenue stood at approximately US$67.7 million, while management has indicated estimated full-year 2026 revenue of around US$116 million.

These numbers remain subject to independent verification during the due diligence process.

Share Swap Proposed for the Acquisition

Blue Cloud Softech plans to fund the proposed acquisition through a share swap, rather than an upfront cash purchase.

Under the proposed structure, Blue Cloud would issue equity shares on a preferential basis to the sellers or shareholders of CareTech AI as consideration for the acquisition.

The exact number of shares and transaction valuation have not yet been finalised. They will be determined after an independent valuation and fairness opinion, followed by negotiations and execution of definitive agreements.

The company has authorised the appointment of a SEBI-registered valuer, merchant banker and due diligence advisers. A Board committee will oversee negotiations and the diligence process.

No Binding Agreement Yet

The proposed CareTech AI acquisition is still at an early stage.

Blue Cloud Softech has clarified that no letter of intent, term sheet or binding agreement has been executed as of the announcement.

The transaction remains subject to:

• Satisfactory due diligence
• Independent valuation
• Fairness opinion
• Definitive agreements
• Shareholder approval
• Stock exchange approvals
• Other applicable regulatory approvals

This means the proposed acquisition may change in terms or may not ultimately be completed.

Why CareTech AI Matters to Blue Cloud Softech

The proposed transaction would give Blue Cloud Softech access to an established US healthcare technology ecosystem.

CareTech AI’s healthcare workforce platform could provide a base for Blue Cloud to deploy and expand its own healthcare technology platforms, subject to customer requirements and applicable approvals.

The deal also fits with Blue Cloud’s wider strategy of building an AI-led technology business across healthcare, public safety and digital infrastructure.

The company recently expanded its international operations and commenced execution of a US$150 million SpaceX engagement covering AI infrastructure, cybersecurity, telecommunications and data centre solutions.

Blue Cloud Softech’s Growing AI Business

Blue Cloud Softech is headquartered in Hyderabad and operates across India, the United States, Africa and other international markets.

Its portfolio includes AI infrastructure and MLOps, cybersecurity, telecommunications and 5G solutions, healthcare technology, data centre services and public-sector digital platforms.

The company also began trading on the NSE Main Board under the symbol BLUECLOUDS from August 17, 2026, adding a second major exchange to its existing BSE listing.

What Investors Should Watch

The proposed CareTech AI transaction could give Blue Cloud Softech a stronger foothold in the US healthcare technology market, but investors will need to track the deal’s next stages.

The key developments will be the independent valuation, share-swap ratio, definitive agreement, shareholder approval and regulatory clearances.

The financial figures cited for CareTech AI are management estimates and will need to be independently verified before the transaction is completed.

For Blue Cloud shareholders, the eventual valuation and number of shares issued will also be important because the share-swap structure could affect the company’s equity base.

Key Highlights

Particular	Details
Acquirer	Blue Cloud Softech Solutions
Target	CareTech AI Inc.
Target subsidiaries	CareCareer Tech LLC, Envision NJ LLC
Proposed stake	Up to 100%
Consideration	Share swap
2025 revenue	US$80.2 million
7M 2026 revenue	US$67.7 million
FY2026E revenue	US$116 million
Transaction status	In-principle approval
Binding agreement	Not yet executed
NSE Symbol	BLUECLOUDS
BSE Code	539607

Bottom Line

Blue Cloud Softech’s proposed acquisition of CareTech AI could add a sizeable US healthcare technology business to its growing AI portfolio.

CareTech AI’s reported US$80.2 million revenue in 2025 and estimated US$116 million revenue for 2026 make the proposed transaction significant in scale. The share-swap structure also means the eventual valuation and number of shares issued will be closely watched.

For now, the transaction remains a proposal under evaluation. The next major triggers will be due diligence, valuation, definitive agreements and regulatory approvals.

FAQs

What is Blue Cloud Softech proposing to acquire?

Blue Cloud Softech is evaluating the acquisition of up to 100% of CareTech AI Inc., along with its subsidiaries CareCareer Tech LLC and Envision NJ LLC.

How will Blue Cloud Softech pay for the acquisition?

The proposed consideration will be paid through a share swap involving preferential allotment of Blue Cloud Softech equity shares.

What is CareTech AI’s revenue?

CareTech AI’s management has indicated revenue of approximately US$80.2 million for 2025, US$67.7 million for the 7 months ended July 2026 and estimated 2026 revenue of US$116 million.

Has Blue Cloud Softech completed the acquisition?

No. The Board has granted in-principle approval to evaluate and negotiate the transaction. No binding agreement has been executed yet.

What are the next steps?

The company will undertake due diligence, obtain an independent valuation and fairness opinion, negotiate definitive agreements and seek the required corporate, shareholder, stock exchange and regulatory approvals.

For more such information visit EQMint

Join our Whatsapp channel for timely updates: Whatsapp 

Disclaimer: This article is not an investment advice and is for educational purpose only.